Stocks Health care AVBP
NASDAQ · Health careArriVent BioPharma, Inc. (AVBP)
It posted a net loss of $163.7M. At June 30, 2026 it held $154.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What ArriVent BioPharma, Inc. does
ArriVent BioPharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AVBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$166.3M | -$4.32 | n/a |
| 2024 | n/a | -$80.5M | -$2.56 | n/a |
| 2024 | n/a | -$69.3M | -$32.38 | n/a |
Latest SEC filings
What ArriVent BioPharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- June 22, 2026
- May 11, 2026Other event 8-K
- May 11, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- May 6, 2026Passive stake changed SCHEDULE 13G/A
- April 28, 2026
Questions about AVBP
What does ArriVent BioPharma, Inc. do?
ArriVent BioPharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AVBP.
Is ArriVent BioPharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $163.7M.
When did ArriVent BioPharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026.
Similar companies
Follow AVBP
Get an email when ArriVent BioPharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AVBP: get an email when it filesWhere the numbers come from
Financial figures are the values ArriVent BioPharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.